SLC5A2 and type 2 diabetes mellitus: Although these contemporary medications have demonstrated reduced HF outcomes, they have not cured the underlying disease as evidenced by the EMPEROR-Reduced trial [95] in which 22% of patients with T2D still reached primary endpoint of cardiovascular death or hospitalization for HF despite being on recommended therapy in addition to an SGLT-2 inhibitor.